UH Seidman Cancer Center Researchers Participate in trial of Newly FDA Approved Non-Small Cell Lung Cancer Drug in Rare Form of Advanced Pancreatic Cancer

Thursday, January 26, 2023

Findings published in the New England Journal of Medicine

CLEVELAND - A drug that recently received accelerated approval from the U.S. Food and Drug Administration to treat a form of non-small cell lung cancer caused by a unique genetic mutation also appears to be effective against advanced pancreatic cancer caused by the same uncommon mutation. That is the conclusion of a study recently published in the New England Journal of Medicine, co-authored by UH Seidman Cancer Center’s David Bajor, MD. KRAS p.G12C mutation occurs in approximately 1 to 2 percent of pancreatic cancers.

The safety and efficacy of the study medicine sotorasib, a KRAS G12C inhibitor, had previously been unknown among previously treated patients with KRAS p.G12C–mutated pancreatic cancer. Study results show that sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C–mutated advanced pancreatic cancer who had received previous treatment. The research team says that these results are quite promising and suggest that inhibitors could even be developed for KRAS mutations that are linked to more common forms of pancreatic cancer.

<< Back
  • News Media Access

  • Register
  • Forgot My Password
  • Search:

    Advanced Search

  • Subscribe To Our Latest News

    Subscribe to University Hospitals' RSS Feeds or Email Alerts to get our latest news.

    University Hospitals RSS Feed  University Hospitals Email Alerts
  • Twitter

    Must select a Twitter Account for Rail Gadget in Twitter Tool.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.